Who makes A: M207 3.8mg, 30 min, upper arm?

A: M207 3.8mg, 30 min, upper arm is developed by Zosano Pharma Corporation.

What development phase is A: M207 3.8mg, 30 min, upper arm in?

A: M207 3.8mg, 30 min, upper arm is in Phase 1.

Last reviewed 2026-04-23 · How we verify

A: M207 3.8mg, 30 min, upper arm

Zosano Pharma Corporation · Phase 1 active Small molecule

At a glance

Generic name	A: M207 3.8mg, 30 min, upper arm
Also known as	A: Zolmitriptan patch, 3.8 mg, 30 min, upper arm
Sponsor	Zosano Pharma Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

A: M207 3.8mg, 30 min, upper arm CI brief — competitive landscape report
A: M207 3.8mg, 30 min, upper arm updates RSS · CI watch RSS
Zosano Pharma Corporation portfolio CI